Moreover, reversing resistance due to p53 debilitation could also arise as a therapeutic strategy in these cancers, should modulators of the MDM2/p53 pathway reach the clinic, and p53 deficiency may also be a synthetic lethal vulnerability [76]. This evidence concerns the gene TP53 and cancer.